Clinical Trial Update: Open-Label, Safety Study of Lofexidine [Phase 3]

View source ↗

Summary

Open-label safety study of lofexidine in opioid withdrawal completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Withdrawal

Drugs mentioned

• LOFEXIDINE (LOFEXIDINE)

Snippet

Sponsor: USWM, LLC (dba US WorldMeds) | Conditions: Opioid Withdrawal | Phase 3 | Status: COMPLETED | Results posted: 2021-04-26